Economic impact of generic antiretrovirals in France for HIV patients’ care: a simulation between 2019 and 2023

Economic impact of generic antiretrovirals in France for HIV patients’ care: a simulation between 2019 and 2023

Background: In a context where the economic burden of HIV is increasing as HIV patients now have a close to normal lifespan, the availability of generic antiretrovirals commonly prescribed in 2017 and the imminence of patent expiration are expected to provide substantial savings in the coming years....

Full description

Bibliographic Details
Main Authors: Allavena, C. (Author), Costa, N. (Author), Cuzin, L. (Author), Dellamonica, P. (Author), Delpierre, C. (Author), Demeulemeester, R. (Author), Molinier, L. (Author), Mounié, M. (Author), Pugliesse, P. (Author), Saint-Pierre, P. (Author), Savy, N. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
adult
Agent-based model
article
budget
economic evaluation
Economic evaluation
France
funding
Generic antiretrovirals
HIV
human
Human immunodeficiency virus infected patient
lifespan
marketing authorization
patent
pre-exposure prophylaxis
price
resource allocation
sensitivity analysis
simulation
Simulations
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items